MannKind Corp NNFN-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 8:00 AM CEST
3.88quote price arrow up+0.18 (+4.85%)
52 week range
2.32 - 4.61
Loading...
  • Open3.88
  • Day High3.88
  • Day Low3.88
  • Prev Close4.00
  • 52 Week High4.61
  • 52 Week High Date10/14/21
  • 52 Week Low2.32
  • 52 Week Low Date02/28/22

Key Stats

  • Market Cap928.88M
  • Shares Out252.41M
  • 10 Day Average Volume3,722.9
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change1.69

KEY STATS

  • Open3.88
  • Day High3.88
  • Day Low3.88
  • Prev Close4.00
  • 52 Week High4.61
  • 52 Week High Date10/14/21
  • 52 Week Low2.32
  • 52 Week Low Date02/28/22
  • Market Cap928.88M
  • Shares Out252.41M
  • 10 Day Average Volume3,722.9
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change1.69

RATIOS/PROFITABILITY

  • EPS (TTM)-0.34
  • P/E (TTM)-11.42
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On MannKind Corp

There is no recent news for this security.

Profile

MORE
MannKind Corporation is a biopharmaceutical company. The Company is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler....
James Shannon M.D.
Independent Chairman of the Board
Michael Castagna Pharm.D.
Chief Executive Officer, Director
Steven Binder CPA
Chief Financial Officer
Joseph Kocinsky
Chief Technology Officer
David Thomson J.D., Ph.D.
Executive Vice President, General Counsel, Secretary
Address
1 CASPER STREET
Danbury, CT
06810
United States